Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

BACKGROUND: Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c(+) myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., Gerritsen, Winald R.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854814/
https://ncbi.nlm.nih.gov/pubmed/31727154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0787-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares